This is a working overview of Drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-08 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Half-Life: Opposing Force is an expansion pack for the first-person shooter game Half-Life (1998). It was developed by Gearbox Software and published by Sierra On-Line for Windows on November 19, 1999. Opposing Force was the first expansion for Half-Life and was announced in April 1999. Lead designer Randy Pitchford believed Gearbox was selected to develop Opposing Force because Valve, the creators of Half-Life, wanted to concentrate on their future projects. Over the course of development, Gearbox brought in a variety of talent from other areas of the video games industry to help bolster various aspects of design. Opposing Force portrays the events of Half-Life from the perspective of a U.S. Marine, one of the enemy characters in the original, assigned to the Hazardous Environment Combat Unit (HECU). The player character, Adrian Shephard, is sent in to neutralize the Black Mesa Research Facility when a scientific mishap causes it to be invaded by aliens, but quickly finds that the Marines are outnumbered and slowly being beaten back by a second alien race and black operations units. Opposing Force was received well by critics, with many describing it as the new benchmark title for expansion packs, in a similar fashion to how Half-Life revolutionized the first-person shooter genre. Other reviewers, however, thought that, despite its accomplishments, it still suffered from the negative aspects of other expansion packs.
== Mechanism == It is a member of the secretin family of G protein-coupled receptors. The activity of this receptor is mediated by Gs protein, which activates adenylyl cyclase. Besides this, they also activate the phosphatidylinositol-calcium second messenger system.
=== Food, beverage and pharmaceutical industries === Concentration and purity measurements are especially important to determine product or ingredient quality in the food & beverage and pharmaceutical industries. Samples that display specific rotations that can be calculated for purity with a polarimeter include:
=== Biochemistry === Estrogen and growth hormone (GH) are essential for the ductal component of mammary gland development, and act synergistically to mediate it. Neither estrogen nor GH are capable of inducing ductal development without the other. The role of GH in ductal development has been found to be mostly mediated by its induction of the secretion of insulin-like growth factor 1 (IGF-1), which occurs both systemically (mainly originating from the liver) and locally in the mammary fat pad through activation of the growth hormone receptor (GHR). However, GH itself also acts independently of IGF-1 to stimulate ductal development by upregulating estrogen receptor (ER) expression in mammary gland tissue, which is a downstream effect of mammary gland GHR activation. In any case, unlike IGF-1, GH itself is not essential for mammary gland development, and IGF-1 in conjunction with estrogen can induce normal mammary gland development without the presence of GH. In addition to IGF-1, other paracrine growth factors such as epidermal growth factor (EGF), transforming growth factor beta (TGF-β), amphiregulin, fibroblast growth factor (FGF), and hepatocyte growth factor (HGF) are involved in breast development as mediators downstream to sex hormones and GH/IGF-1. During embryonic development, IGF-1 levels are low, and gradually increase from birth to puberty. At puberty, the levels of GH and IGF-1 reach their highest levels in life and estrogen begins to be secreted in high amounts in females, which is when ductal development mostly takes place.
Sources: en.wikipedia.org
==== Psychiatry and neuropsychopharmacology ==== Numerous compounds that bind selectively to neuroreceptors of interest in biological psychiatry have been radiolabeled with C-11 or F-18. Radioligands that bind to dopamine receptors (D1, D2, reuptake transporter), serotonin receptors (5HT1A, 5HT2A, reuptake transporter), opioid receptors (mu and kappa), cholinergic receptors (nicotinic and muscarinic) and other sites have been used successfully in studies with human subjects. Studies have been performed examining the state of these receptors in patients compared to healthy controls in schizophrenia, substance abuse, mood disorders and other psychiatric conditions.
== Structure == The chondrocyte in cartilage matrix has rounded or polygonal structure. The exception occurs at tissue boundaries, for example the articular surfaces of joints, in which chondrocytes may be flattened or discoid. Intra-cellular features are characteristic of a synthetically active cell. The cell density of full-thickness, human, adult, femoral condyle cartilage is maintained at 14.5 (±3.0) × 103 cells/ mm2 from age 20 to 30 years. Although chondrocyte senescence occurs with aging, mitotic figures are not seen in normal adult articular cartilage. The structure, density, and synthetic activity of an adult chondrocyte are various according to its position. Flattened cells are oriented parallel to the surface, along with the collagen fibers, in the superficial zone, the region of highest cell density. In the middle zone, chondrocytes are larger and more rounded and display a random distribution, in which the collagen fibers also are more randomly arranged. In the deeper zones, chondrocytes form columns that are oriented perpendicular to the cartilage surface, along with the collagen fibers. Different behaviors may be exhibited by chondrocytes depending on their position within the different layers. In primary chondrocyte cultures, these zonal differences in synthetic properties may persist. The primary cilia are significant for spatial orientation of cells in developing growth plate and are sensory organelles in chondrocytes. Primary cilia work as centers for wingless type (Wnt) and hedgehog signaling and contain mechanosensitive receptors.
== See also == Chronic diseases and cancers linked to infectious microbes List of oncogenic bacteria List of epidemics and pandemics List of causes of death by rate − including specific infectious diseases and classes thereof List of human disease case fatality rates List of vaccine topics
Aurora is one of the most ancient districts which developed out of the medieval city walls, north of the historical city centre. It stretches from downtown northern boundaries in Corso Regina Margherita (an extended and important thoroughfare of Turin) up to Corso Vigevano and Corso Novara in the North Side (namely the old excise boundary until the early 20th century); the western boundary is Corso Principe Oddone (now part of the Spina Centrale boulevard) and the eastern border is the River Dora. The district was named Aurora after the so-called Cascina Aurora, an old farmstead lying north of the River Dora, right at the intersection between Corso Giulio Cesare and Corso Emilia. The farmstead has long been demolished and the area has been converted to office buildings, hosting the Turinese textile company Gruppo Finanziario Tessile (GFT) headquarters until the early 21st century. The historical hub of the district is Borgo Dora (The 'Dora Borough'), a small neighbourhood next to Porta Palazzo and enclosed by Corso Regina Margherita, Via Cigna, the River Dora and Corso Giulio Cesare. Once known as Borgo del Pallone ('Ball Borough') or Balon in Piedmontese dialect (locally [baˈlun]), this neighbourhood is known for its mercatino del Balon or simply Balon, the Turinese flea market that opens every Saturday in its tiny and twisted streets.
=== 10 January === Ukrainian steel production was reduced by about 70% in 2022 as a result of the conflict. US and Ukrainian officials stated that Russian artillery fire had declined nearly 75% in some places. The UK said most of Soledar was under Russian control, whereas Wagner claimed all.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.